info@RegenProtocols.com
561-325-7000
141 NW 20th St., Suite G1 Boca Raton, FL 33431
A long-duration regenerative framework for chronic musculoskeletal pain, with sustained anti-inflammatory support and sleep-optimized recovery.
A long-duration regenerative framework for chronic musculoskeletal pain and degenerative soft tissue conditions. The protocol emphasizes sustained anti-inflammatory modulation, connective tissue remodeling, and sleep-optimized recovery over an extended treatment window.
Unlike acute protocols, this approach prioritizes compliance, gradual tissue repair, and long-term functional stabilization.
| Agent | Route | Dose | Frequency | Duration |
|---|---|---|---|---|
| BPC-157 | SubQ and oral | 250 mcg SubQ + 250 mcg oral | Twice daily | 12–16 weeks |
| TB-500 (thymosin β4) | SubQ | 1.0–1.5 mg | Once weekly | 12 weeks |
| KPV | Oral | 500 mcg | Daily | 8–12 weeks |
| CJC-1295 / Ipamorelin | SubQ | 100 mcg / 100 mcg | Once daily (evening) | 16 weeks |
| DSIP | SubQ | 100–200 mcg | Nightly (before bed) | 4–8 weeks (front-loaded) |
Chronic musculoskeletal pain needs a slower, sustained approach than acute protocols. Splitting BPC-157 between oral and SubQ routes provides systemic anti-inflammatory modulation through the gut-brain axis while supporting localized tissue repair.
TB-500 enhances cell migration and long-term structural remodeling. KPV offers controlled inflammatory regulation without systemic suppression. CJC-1295/ipamorelin continue for the full duration to support ongoing tissue remodeling through growth hormone and IGF-1 signaling. DSIP is front-loaded to break the cycle of pain and poor sleep and to improve recovery early in treatment.
